SafeRide Health (SRH) is the new provider for all NEMT rides to doctor appointments and pharmacy visits.
Depending on your needs, rides may include wheelchair-lift-equipped vehicles, stretcher vans, minivans, or ambulatory vans. Please let SRH know what type of ride you need when scheduling.
SafeRide Health (SRH) es el nuevo proveedor de todos los servicios de transporte médico que no son de emergencia (NEMT, por sus siglas en inglés) hacia consultas médicas y farmacias.
Según tus necesidades, los servicios de transporte pueden incluir vehículos con elevador para sillas de ruedas, camionetas con camilla, minivans o camionetas ambulatorias. Por favor, informa a SRH qué tipo de transporte necesitas al programar tu traslado.
PDL Prior Authorization Criteria Revisions Scheduled for October 11
Date: October 11, 2022 Attention: All ProvidersEffective Date: October 11, 2022Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event.
Call to action: Effective October 11, 2022, Texas Children's Health Plan (TCHP) will revise the preferred drug list (PDL) prior authorization criteria guide for the Bronchodilators, Beta Agonists, and Glucagon Agents drug classes. These changes will modify the duration of treatment with a preferred agent in each of these drug classes.
How this impacts providers: Currently, the PDL criteria requires a 30-day treatment trial with at least 1 preferred agent. Beginning October 11, 2022, TCHP will revise step one of the PDL prior authorization criteria to require a 14-day treatment trial with a preferred agent for the Bronchodilators, Beta Agonists, and a one-day treatment trial with a preferred agent for the Glucagon Agents
For the Bronchodilators, Beta Agonists PDL criteria, step one will require a treatment failure after a 14-day trial with at least one preferred agent in the last 180 days. Some preferred agents include Proventil HFA, Ventolin HFA, Albuterol nebulizer.
For the Glucagon Agents PDL criteria, step one will require a one-day treatment trial with at least one preferred agent in the last 180 days. Some preferred agents include Baqsimi, Glucagon injection, Glucagon emergency kit, Gvoke syringe, Proglycem and Zegalogue.
